Trial of pig cell transplants for Parkinson’s approved
Choroid plexus cells will be transplanted in a phase 1 open label study of NTCELL, a product of the NZ-based company Living Cell Technologies.
The company’s chief executive, Dr Andrea Grant, said in a statement yesterday it had received approval from the NZ Health Minister for the trial to start early next year.
Patients would receive either the pig cells or the current “gold standard of treatment”, deep brain stimulation.
Dr Grant said pre-clinical trials suggested the NTCELL treatment can protect brain tissue which would otherwise die, potentially delaying or preventing